Diagnostic Performance of the S100B Protein in the Prognosis of Patients With Mild Head Trauma With Risk of Complications in Patients Over 65 Years Old.

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05091125
Collaborator
(none)
300
36

Study Details

Study Description

Brief Summary

For patients with mild head trauma, a large number of CT scans are performed. The S100B protein allows, when the dosage is below the threshold, to rule out the diagnosis of brain damage with a negative predictive value of 98%.

In patients over 65 years old it was found that the dosage of S100B came back positive more often compared to a younger population.

This study proposes to determine the positivity threshold value for S100B dosage in patients over 65 years old. In patients over 65 years suffering from mild head trauma, a head CT will systematically be performed (in accordance with the recommendations) and the S100B will be measured (taken from an additional tube on the blood test carried out in these patients). The results of the TDM will then be compared with the results of the S100B to determine the values of sensitivity, specificity, negative and positive predictive value of different thresholds.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Diagnostic performance of the S100B protein dosage

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Performance of the S100B Protein in the Prognosis of Patients With Mild Head Trauma With Risk of Complications in Patients Over 65 Years Old.
Anticipated Study Start Date :
Nov 2, 2021
Anticipated Primary Completion Date :
Nov 2, 2024
Anticipated Study Completion Date :
Nov 2, 2024

Arms and Interventions

Arm Intervention/Treatment
Patients over 65 years old who have undergone a mild head trauma.

Diagnostic Test: Diagnostic performance of the S100B protein dosage
Dosage of the S100B protein in patients with mild head trauma with complication risks

Outcome Measures

Primary Outcome Measures

  1. The threshold of the S100B protein [This outcome measure is assessed on Day 1.]

Secondary Outcome Measures

  1. - Sensitivity (Se) and Specificity (Sp) of the S100B protein in the differential diagnosis of bleeding - Positive predictive value and negative predictive value of the S100B protein in the differential diagnosis of hemorrhage [This outcome measure is assessed on Day 1.]

    Sensitivity (Se) and Specificity (Sp) of the S100B protein in the differential diagnosis of bleeding in patients over 65 years old who have undergone a mild head trauma. Positive predictive value and negative predictive value of the S100B protein in the differential diagnosis of hemorrhage in patients over 65 years old who have undergone a mild head trauma.

Eligibility Criteria

Criteria

Ages Eligible for Study:
62 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female aged 65 or more

  • Patients going to the emergency for a mild head trauma with risk of complication and treated within 3 hours of the head injury, according to the following criteria:

  • Adult patients with head trauma presenting:

  • Retrograde amnesia lasting more than 30 min, Or

  • A loss of consciousness or amnesia of the facts Or

  • Glasgow score <15 to 2 hours from traumatism

  • Speaking and reading French

  • Subject having expressed his non-opposition to the research or non-opposition given by a trusted person / member of his family in cases where the patient is not in a position to express his non-opposition.

  • Subject affiliated to a social health insurance protection scheme

Exclusion Criteria:
  • Severe head trauma

  • Mild head trauma without risk of complication

  • Patient under the protection of justice

  • Patient under guardianship, curatorship

  • Subject in exclusion period (determined by a previous or current study)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Strasbourg, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT05091125
Other Study ID Numbers:
  • 8112
First Posted:
Oct 25, 2021
Last Update Posted:
Oct 25, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 25, 2021